Positron emission tomography imaging in nonmalignant thoracic disorders

Abass Alavi, Naresh Gupta, Jean Louis Alberini, Marc Hickeson, Lars Eric Adam, Peeyush Bhargava, Hongming Zhuang

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.

Original languageEnglish (US)
Pages (from-to)293-321
Number of pages29
JournalSeminars in Nuclear Medicine
Volume32
Issue number4
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Thorax
Asbestosis
Fever of Unknown Origin
Chronic Granulomatous Disease
Pneumoconiosis
Lung
Aptitude
Pleura
Sarcoidosis
Trachea
Thymus Gland
Esophagus
Lung Diseases
Aorta
Lung Neoplasms
Pneumonia
Acquired Immunodeficiency Syndrome
Radiotherapy
Asthma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Alavi, A., Gupta, N., Alberini, J. L., Hickeson, M., Adam, L. E., Bhargava, P., & Zhuang, H. (2002). Positron emission tomography imaging in nonmalignant thoracic disorders. Seminars in Nuclear Medicine, 32(4), 293-321. https://doi.org/10.1053/snuc.2002.127291

Positron emission tomography imaging in nonmalignant thoracic disorders. / Alavi, Abass; Gupta, Naresh; Alberini, Jean Louis; Hickeson, Marc; Adam, Lars Eric; Bhargava, Peeyush; Zhuang, Hongming.

In: Seminars in Nuclear Medicine, Vol. 32, No. 4, 01.01.2002, p. 293-321.

Research output: Contribution to journalArticle

Alavi, A, Gupta, N, Alberini, JL, Hickeson, M, Adam, LE, Bhargava, P & Zhuang, H 2002, 'Positron emission tomography imaging in nonmalignant thoracic disorders', Seminars in Nuclear Medicine, vol. 32, no. 4, pp. 293-321. https://doi.org/10.1053/snuc.2002.127291
Alavi, Abass ; Gupta, Naresh ; Alberini, Jean Louis ; Hickeson, Marc ; Adam, Lars Eric ; Bhargava, Peeyush ; Zhuang, Hongming. / Positron emission tomography imaging in nonmalignant thoracic disorders. In: Seminars in Nuclear Medicine. 2002 ; Vol. 32, No. 4. pp. 293-321.
@article{4b9949848d4d4a8e8e23d0ab375f985c,
title = "Positron emission tomography imaging in nonmalignant thoracic disorders",
abstract = "The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.",
author = "Abass Alavi and Naresh Gupta and Alberini, {Jean Louis} and Marc Hickeson and Adam, {Lars Eric} and Peeyush Bhargava and Hongming Zhuang",
year = "2002",
month = "1",
day = "1",
doi = "10.1053/snuc.2002.127291",
language = "English (US)",
volume = "32",
pages = "293--321",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Positron emission tomography imaging in nonmalignant thoracic disorders

AU - Alavi, Abass

AU - Gupta, Naresh

AU - Alberini, Jean Louis

AU - Hickeson, Marc

AU - Adam, Lars Eric

AU - Bhargava, Peeyush

AU - Zhuang, Hongming

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.

AB - The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.

UR - http://www.scopus.com/inward/record.url?scp=0036809601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036809601&partnerID=8YFLogxK

U2 - 10.1053/snuc.2002.127291

DO - 10.1053/snuc.2002.127291

M3 - Article

C2 - 12524653

AN - SCOPUS:0036809601

VL - 32

SP - 293

EP - 321

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 4

ER -